{"id":7170,"date":"2022-03-29T07:56:47","date_gmt":"2022-03-29T05:56:47","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf"},"modified":"2022-03-29T07:56:47","modified_gmt":"2022-03-29T05:56:47","slug":"220328_en-maat-pharma_pr-phase3launch_finalversion","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-first-patient-dosed-in-phase-3-ares-trial-evaluating-maat013-in-patients-with-acute-graft-vs-host-disease\/220328_en-maat-pharma_pr-phase3launch_finalversion\/","title":{"rendered":"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-7170","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf\",\"name\":\"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2022-03-29T05:56:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces First Patient Dosed in Phase 3 \u2018ARES\u2019 Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease\",\"item\":\"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-first-patient-dosed-in-phase-3-ares-trial-evaluating-maat013-in-patients-with-acute-graft-vs-host-disease\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf","name":"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2022-03-29T05:56:47+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces First Patient Dosed in Phase 3 \u2018ARES\u2019 Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease","item":"https:\/\/www.seventure.fr\/en\/maat-pharma-announces-first-patient-dosed-in-phase-3-ares-trial-evaluating-maat013-in-patients-with-acute-graft-vs-host-disease\/"},{"@type":"ListItem","position":3,"name":"220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf'>220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion<\/a><\/p>\n"},"caption":{"rendered":"<p>220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{},"post":7169,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2022\/03\/220328_EN-MaaT-Pharma_PR-Phase3Launch_FinalVersion.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/7170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=7170"}]}}